Finding. A polyamine-catabolic switch can put glioblastoma stem cells to sleep, and it uses a mitochondrial antiviral protein to do it. Chesnelong, Dirks and colleagues find SAT1, encoding SSAT1, enriched in quiescent GSCs. Push the enzyme with N1,N11-diethylnorspermine and patient-derived GSCs arrest. The arrest is reversible and chemoprotective. It is not stemness loss, differentiation, or senescence. Translation falls with eIF5A hypusination. Double-stranded RNA rises and type I interferon comes on. Knock down mitochondrial antiviral-signalling protein (MAVS) and the arrest partly lets go. Viral mimicry, read at the mitochondrial outer membrane, is required. Who is susceptible is already written: inflammatory tone and lysosomal dependency, in GSCs and neural stem cells.
Why this paper matters
Dormant GSCs are why glioblastoma returns. A metabolic handle that creates dormancy is only useful if you know it can also hide the cell from chemotherapy. The authors say chemoprotective out loud. The mitochondrial handle is MAVS, which puts this paper next to viral-mimicry and mitochondrial-dsRNA work, not next to a Complex I inhibitor.
What they actually measured
SAT1 enrichment, DENSpm pharmacology, translation/hypusine, dsRNA/IFN, MAVS knockdown, single-cell and cohort context. Partial rescue is the honest functional word.
How to read the score
Mid 80s. MAVS requirement plus a quiescence program in patient GSCs. Confidence is high for the dish circuit.
Caveats
Chemoprotection is a warning. Partial MAVS means leftover paths. No in vivo DENSpm/MAVS experiment in the abstract.
What to do with it
If you track GSC dormancy, add SAT1, hypusine, dsRNA, and MAVS to the panel. If you give polyamine analogues, watch for reversible arrest rather than death. Do not combine DENSpm with temozolomide hoping for synergy from this brief; the paper says the opposite risk.